コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 a, with lifestyle and hygiene standards of a developed country.
2 ion and skin prick test reactivity even in a developed country.
3 are older and live in a rural area of a less developed country.
4 are problem worldwide both in developing and developed countries.
5 ion (AMD) is a leading cause of blindness in developed countries.
6 lignancy of the genital tract among women in developed countries.
7 e, similar to what is seen in humans in less developed countries.
8 challenges of hospital Ebola preparation in developed countries.
9 butes enormously to the burden of disease in developed countries.
10 fecting about one-third of the population in developed countries.
11 use of acquired heart disease in children in developed countries.
12 the leading cause of infectious blindness in developed countries.
13 and HFpEF) is the leading cause of death in developed countries.
14 r and its precursors are highly prevalent in developed countries.
15 ERD) is prevalent worldwide, particularly in developed countries.
16 (HPV) vaccines have been introduced in most developed countries.
17 correctable vision loss among the elderly in developed countries.
18 ma (HCC) incidence is rising rapidly in many developed countries.
19 leading cause of pediatric heart disease in developed countries.
20 ern countries, and access is limited in less developed countries.
21 together remain a leading cause of death in developed countries.
22 ble illness and death in both developing and developed countries.
23 emain substantially higher than are those in developed countries.
24 dity and mortality of sickle-cell disease in developed countries.
25 est tests for meningitis and encephalitis in developed countries.
26 ncer (PCA) is a serious health issue in most developed countries.
27 Obesity is a growing epidemic in developed countries.
28 mong generic oncology drugs were reported in developed countries.
29 he leading source of infectious blindness in developed countries.
30 the most common hematological malignancy in developed countries.
31 sible visual impairment and blindness in the developed countries.
32 the rapid increase in the incidence of AD in developed countries.
33 oportion of adenocarcinomas, particularly in developed countries.
34 ons also occur in infants and the elderly in developed countries.
35 in low resource settings, especially in less developed countries.
36 s in Chinese adults were much higher than in developed countries.
37 reast cancers has increased steadily in most developed countries.
38 nd plasma derived, are emerging, at least in developed countries.
39 IE) occurs in 1 to 8 per 1000 live births in developed countries.
40 s have compared the United States with other developed countries.
41 e cancer landscape in Latin America and more developed countries.
42 ntries, and in the Indigenous populations of developed countries.
43 inue to be the primary cause of mortality in developed countries.
44 te on humans and currently resurgent in many developed countries.
45 radic encephalitis and blinding keratitis in developed countries.
46 the condition of low aerosol mass loading in developed countries.
47 e leading cause of irreversible blindness in developed countries.
48 g programs are possible only in economically developed countries.
49 rom sepsis is increasing in the UK and other developed countries.
50 al and population concern in the majority of developed countries.
51 life-threatening disease worldwide, even in developed countries.
52 h to men is stronger in more egalitarian and developed countries.
53 use of these agents in children with AGE in developed countries.
54 is the leading cause of preventable death in developed countries.
55 (AMD) is the leading cause of vision loss in developed countries.
56 t are different from those typically used in developed countries.
57 ues relevant to reduction of child deaths in developed countries.
58 er damage requiring liver transplantation in developed countries.
59 plantation in some countries rivals those in developed countries.
60 clinical use of probiotics in outpatients in developed countries.
61 ignificant and likely to be similar in other developed countries.
62 ndemic hepatitis E (HE) has been reported in developed countries.
63 ealth, and the economy in developed and less developed countries.
64 ortality has fallen to very low rates in all developed countries.
65 out the world, now ranging from 10 to 20% in developed countries.
66 e strategy with currently available drugs in developed countries.
67 g in OS and DFS similar to those reported in developed countries.
68 g 1983 to 2002 predominantly in economically developed countries.
69 iseases for the prevention of vision loss in developed countries.
70 related with antimicrobial resistance within developed countries.
71 n reasons for emergency department visits in developed countries.
72 be different from those in larger cities and developed countries.
73 ith growth faltering seen in infants in less-developed countries.
74 tributed to a plateau in stillbirth rates in developed countries.
75 Stroke is the leading cause of disability in developed countries.
76 ociated complications are relatively rare in developed countries.
77 most frequently diagnosed cancer in males in developed countries.
78 ion during pregnancy is a common practice in developed countries.
79 % for children treated on clinical trials in developed countries.
80 hepatitis C virus (HCV) transmission in most developed countries.
81 cause of food and waterborne illness in the developed countries.
82 particularly in the United States and other developed countries.
83 y is a major health concern, particularly in developed countries.
84 ty) and the implications for human health in developed countries.
85 now responsible for 2-3% of children born in developed countries.
86 rom other international studies conducted in developed countries.
87 isease-related cause of death in children in developed countries.
88 ave lower efficacy in developing compared to developed countries.
89 research laboratories in developing and less developed countries.
90 atically in the last several decades in most developed countries.
91 e most common and deadly sterile injuries in developed countries.
92 le for food-induced anaphylaxis in adults in developed countries.
93 tor for most of the major killer diseases in developed countries.
94 s in low-resource settings are lower than in developed countries.
95 us infection (HEV) is an emerging problem in developed countries.
96 ISK and the financial crisis severity for 23 developed countries.
97 to 0.26 kgCO(2)e/km in the most economically developed countries.
98 e of acquired cardiac disease in children in developed countries.
99 us removal applicable to both developing and developed countries.
100 ic in many countries, and re-emerging in the developed countries.
101 nd one of the leading causes of mortality in developed countries.
102 frican coastal communities-a region of least developed countries.
103 nt years, with a reduction in fleet sizes in developed countries.
104 g cause of neonatal sepsis and meningitis in developed countries.
105 asing public health problem, particularly in developed countries.
106 infectious cause of newborn malformation in developed countries.
107 patients than that reported for patients in developed countries.
108 in low resource settings, especially in less developed countries.
109 the SAGE, but the evidence was largely from developed countries.
110 more pronounced in more egalitarian and more developed countries.
111 s a leading cause of death among newborns in developed countries.
112 patients with ESRD attributed to diabetes in developed countries.
113 lobally and a substantial economic burden in developed countries.
114 cally in the last few decades in westernized developed countries.
115 ature of elevated SES in many populations in developed countries.
116 oth in the USA and between the USA and other developed countries.
117 by accidental gun use than children in other developed countries.
118 egnant women and young children (6-24 mo) in developed countries.
119 that it is often recurrent and is common in developed countries.
120 in low-mortality developing (19%, 16-22) and developed countries (20%, 17-22) compared with high-mort
121 substantially in children and adolescents in developed countries; 23.8% (22.9-24.7) of boys and 22.6%
123 l episodes occur worldwide each year, and in developed countries a considerable part of them are caus
124 ation have been initiated in several, mostly developed, countries across the globe, such as the Unite
125 e interval [CI], 0-2%) of all stillbirths in developed countries and 4% (95% CI, 2%-6%) in Africa wer
127 gic asthma are significant health burdens in developed countries and are increasing in prevalence.
129 common enteric pathogen of cats and dogs in developed countries and infect ~1 billion people worldwi
130 is increasingly prevalent in developing and developed countries and is associated with severe morbid
133 cause of blindness and severe vision loss in developed countries and is responsible for 8.7% of blind
134 he leading causes of enteric disease in many developed countries and is the leading cause of enteric
135 ost common cause of chronic liver disease in developed countries and its incidence is rapidly increas
136 English language published after 1990, from developed countries and of qualitative, quantitative or
138 (CVD) is the leading cause of death in many developed countries and remains one of the major disease
139 the prevalence of end-stage renal disease in developed countries and the shortage of deceased donors
140 rising incidence of this cancer in low-risk developed countries and the strong public health interes
141 a global burden given its high incidence in developed countries and the substantial increase in inci
142 mplexity of VL is preventing scale-up beyond developed countries and there is a lack of awareness amo
143 erences in math performance are now small in developed countries and they cannot explain on their own
144 f irreversible visual loss in the elderly in developed countries and typically affects more than 10%
145 with prevalence rates between 20 and 40% in developed countries and up to 90% in Africa and other de
146 ence in cases to controls could be high in a developed country and close to or even less than 1 in a
147 mokers now outnumber current smokers in many developed countries, and current smokers are smoking few
149 n (AMD) is the leading cause of blindness in developed countries, and is characterized by slow retina
150 is the most common gynaecological tumour in developed countries, and its incidence is increasing.
151 herefore urgently needed, especially in less developed countries, and management of hypertension must
152 (T2D) affect the first world as well as less-developed countries, and now affect children as well.
153 les are the most serious threat to health in developed countries, and public and governmental awarene
154 more for some prescription drugs than other developed countries, and the high price and increasing c
155 one of the leading nosocomial infections in developed countries, and therapeutic choices are limited
156 otective factor in rural populations in less developed countries, and this appears to be the case whe
158 rrently the third leading cause of cancer in developed countries; and is predicted to become the seco
160 , and the current low intakes in most modern developed countries are believed to contribute to a wide
161 with modern multidisciplinary treatments in developed countries are cured; however, of the approxima
162 ost pregnancy hypertension estimates in less-developed countries are from cross-sectional hospital su
163 suggest that many well-assessed fisheries in developed countries are moving toward sustainability.
164 lization and costs of end-of-life care among developed countries are of considerable policy interest.
166 sease), whereas China more closely resembled developed countries (around 80% of DALYs attributable to
167 -like particles have been introduced in many developed countries as a primary prevention strategy.
168 d harms of universal iron supplementation in developed countries as evidenced by the recent conclusio
169 Abuse was equally reported in developing and developed countries as the reason for street involvement
170 e greater access to diagnostic facilities in developed countries as well as POC diagnostics in resour
171 ts was lowest among people born in the least developed countries, as indicated by GNI, where infectio
172 ted air pollution in both developed and less-developed countries, as well as the continued importance
174 ing cause of morbidity and mortality in more developed countries, being the 14th most common cause of
175 en observed in the past 2 decades, mainly in developed countries but also in developing regions.
177 and MRs of these conditions have improved in developed countries, but are increasing in developing co
178 work environment are increasingly common in developed countries, but few exist in developing countri
179 le impacts upon nutrition and food safety in developed countries, but further research is necessary t
180 revalence of peanut allergy has increased in developed countries, but little is known about developin
181 ntly increased during recent decades in some developed countries, but the impact of improved drug tre
182 e same direction as historically occurred in developed countries, but typically had a lower degree of
185 an improve cardiovascular preventive care in developed countries by addressing risk factors including
186 Nearly all patients with retinoblastoma in developed countries can now be cured of their primary ca
190 evidence-based nutrition recommendations in developed countries, concerted worldwide efforts and pol
192 s-transmission takes place in developing and developed countries, contingent upon epidemiological pot
194 al disease dynamics: (i) the worried well in developed countries (demanding less risk while broadenin
195 an increasing problem in both developing and developed countries due to rising incidence, high morbid
196 deficiencies in the testing capacity of many developed countries during the early stages of pandemics
198 ath for HIV-infected persons in economically developed countries, even in the era of antiretroviral t
200 alth care-related HCV outbreaks occurring in developed countries from 1990 to 2012 were collated, gro
201 host immunity and may protect people in less-developed countries from developing immunological diseas
202 hogenesis of AS has undergone transitions in developed countries, from rheumatic heart disease to a d
203 orts on fungal keratitis from developing and developed countries, fungal keratitis in Ethiopia is poo
204 cause of irreversible severe vision loss in developed countries-given the suggestion that a healthy
205 creasing incidence of whooping cough in many developed countries has been linked with waning immunity
206 inational antiretroviral therapies (cART) in developed countries has changed the course of Human Immu
209 mon diagnosis in the United States and other developed countries, has been increasing in prevalence.
211 ever, since the introduction of the vaccine, developed countries have seen the emergence of non-PCV13
212 In contrast to the United States and other developed countries, HCV transmission in developing coun
215 lder than 65 years who died with cancer in 7 developed countries in 2010, end-of-life care was more h
216 atic changes, with continuous improvement in developed countries in North America and Europe, but a c
219 have been developed for protozoa endemic to developed countries, including Giardia lamblia (syn. G.
220 have been developed for protozoa endemic to developed countries, including Giardia lamblia and Crypt
223 on cause of inflammatory cardiomyopathies in developed countries is lymphocytic myocarditis most comm
226 vival for childhood and adolescent cancer in developed countries is now in excess of 80% and the numb
227 ence of nosocomial infections in children in developed countries is still high, ranging from 8% to 30
230 st common cause of acquired heart disease in developed countries, is a self-limited vasculitis that i
231 th, the major cause of neonatal mortality in developed countries, is associated with intrauterine inf
232 evalent and increasingly common condition in developed countries, is associated with significantly lo
233 of the most frequent causes of blindness in developed countries, is strongly associated with aging.
235 hood obesity has become a global pandemic in developed countries, leading to a host of medical condit
236 (EU, landlocked developing countries, least developed countries, low-income food deficit countries,
237 ucrose overconsumption, typical for diets in developed countries, necessitate use of low-calorie swee
240 Zinc is a commonly overlooked deficiency in developed countries, occurring in infants, children, and
241 Phosphorus is abundant in the food supply of developed countries, occurring naturally in protein-rich
242 failure (HF), the leading cause of death in developed countries, occurs in the setting of reduced (H
243 orldwide, and infection of children in under-developed countries often leads to high mortality rates.
244 rforms poorly relative to other economically developed countries on numerous indicators of care quali
245 ecords, nowadays routinely collected in many developed countries, open a new avenue for medical knowl
246 amous cell carcinoma (PSCC) has increased in developed countries over the past decades owing to incre
247 rom 10.4% in low-developed to 6.6% in highly developed countries (P < .0001) and increased from 7.3%
248 eased from 10.4% in low to 6.6% in very high developed countries; p < 0.0001 and increased from 7.3%
254 A literature search identified articles from developed countries published from January 1980 to July
255 disease, the most prevalent liver disease in developed countries, remains difficult to manage with no
257 nsiderable impacts are possible in the least-developed countries, six of which could double or offset
258 g trend in the number of publications, a few developed countries still account for almost one-half of
259 , because susceptibility data originate from developed countries, studies in resource-poor settings u
260 ographically and demographically and that in developed countries, such as the US, SV40 prevalence rat
263 dies with concurrent controls conducted in a developed country that evaluated a primary care-relevant
264 ing in the world (especially in emergent and developed countries), the development of a simple protoc
266 not responding to treatment has declined in developed countries, the prevalence of TDR mutations has
267 dian lifespan extending into the 80s in many developed countries, the societal burden of age-related
268 ojects in a developing country, China, and a developed country, the United States of America, both of
269 nical registries has been well recognized in developed countries, their use for measuring the quality
270 rder incurring the largest societal costs in developed countries, there is a need to gather evidence
271 n 0.05 kgCO(2)e/km in the least economically developed countries to 0.26 kgCO(2)e/km in the most econ
272 ewly presenting to care for HIV infection in developed countries to generate an estimate of the time
273 nd export of agricultural products away from developed countries toward Africa and Latin America.
278 lent pneumococcal conjugate vaccine (PCV) in developed countries was enhanced by indirect protection
279 We found that mean BMI (kg/m(2)) in less-developed countries was generally higher within urban ar
280 vaccine candidates against GBS serotypes of developed countries, we also found their role in the att
282 1,763 birth cohorts from 1800 to 1935 in 13 developed countries, we show that what is now seen as no
283 re to air pollution, especially in cities in developed countries where air pollution is caused predom
284 , since thalassemia is endemic in many under-developed countries where patients have not probably bee
286 es but accounts for less than 5% of cases in developed countries, where idiopathic, presumed viral ca
287 This would suggest that immigrants from less developed countries, where infections are more common, t
288 d cycling are not negligible in economically developed countries which have high dietary-related emis
289 orations with colleagues and centres in more developed countries, who can contribute specialised expe
290 where infections are more common, to highly developed countries will have lower risk of asthma compa
291 g the next 5-10 years, blood availability in developed countries will need to increase again to meet
292 is a relevant emission source even in highly developed countries with a strong focus on water quality
293 ngs and deaths in both developing as well as developed countries with a substantial economic loss.
294 r pediatric cancer diagnosed in economically developed countries with B-cell precursor (BCP)-ALL, acc
295 he "Global North" (the group of economically developed countries with high per capita gross domestic
296 g the HF risk factors and HF epidemiology of developed countries with the added factors of SH, C'D, a
297 now the most common form of liver disease in developed countries, with an estimated prevalence of 20%
298 way in which people use wild fish stocks in developed countries, with inland systems contributing th
299 fastest-growing segment in the population in developed countries, with more than 30 million new cases